Page 2 - Castle Bioscience News Today

The genetic-testing company beat expectations with its Q2 results.

MedTech Acquisition (NASDAQ:MTAC – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends. Analyst Ratings This is a summary of […]

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared... | June 3, 2023

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Analysts forecast that Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) will announce ($0.58) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Castle Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.52). Castle Biosciences posted earnings […]

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) – Research analysts at SVB Leerink lowered their Q2 2022 earnings estimates for shares of Castle Biosciences in a report released on Monday, May 9th. SVB Leerink analyst P. Souda now anticipates that the company will post earnings of ($0.65) per share for the quarter, down from their […]

Brokerages forecast that Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) will announce $25.13 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Castle Biosciences’ earnings. The lowest sales estimate is $24.90 million and the highest is $25.35 million. Castle Biosciences posted sales of $22.81 million during the same […]

Houston-based company will pay $65 million in cash and stock for AltheaDx, which makes a pharmacogenomics tests to guide clinicians on drug therapies for depression and anxiety.

Wall Street brokerages expect that Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) will report $25.13 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Castle Biosciences’ earnings. The lowest sales estimate is $24.90 million and the highest is $25.35 million. Castle Biosciences reported sales of $22.81 million in the […]

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx . A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.